title: A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma.
authors.affiliation: Abert Einstein Cancer Center, Bronx, New York 10461, USA. kaufman@aecom.yu.edu
authors.forename: H L
authors.initials: HL
authors.lastname: Kaufman
authors.forename: G
authors.initials: G
authors.lastname: DeRaffele
authors.forename: J
authors.initials: J
authors.lastname: Divito
authors.forename: H
authors.initials: H
authors.lastname: Hörig
authors.forename: D
authors.initials: D
authors.lastname: Lee
authors.forename: D
authors.initials: D
authors.lastname: Panicali
authors.forename: M
authors.initials: M
authors.lastname: Voulo
mesh_terms: D000293:Adolescent; D000328:Adult; D019496:Cancer Vaccines; D002985:Clinical Protocols; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D006801:Humans; D007258:Informed Consent; D015552:Injections, Intralesional / Q000379:methods; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D020714:Maximum Tolerated Dose; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000628:therapy*; D013223:Statistics as Topic; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D019496:Cancer Vaccines; D014614:Vaccines, Synthetic; C439566:rV-Tricom